samedan logo
 
 
spacer
home > pmps > spring 2018 > digital double-win
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Digital Double-Win

Today’s pharmaceutical executives navigate extremely complex territory on a daily basis. The toughest quandary they face is existential in nature: how to survive and thrive in the digital economy. Digital developments present both risks – including those connected with business, security, and compliance – and tremendous upside performance transformation opportunities.

Industry headlines are forcing executives to think long and hard about their digital transformation strategies. Consider these sample, thought-provoking headlines:

• Why did CVS buy Aetna for $69 billion? (1)
• Mylan and Teva stocks rise on report about Amazon’s pharmacy aims (2)
• Hearing Amazon’s footsteps, the healthcare industry shudders (3)
• Big Pharma builds blockchain prototype to stop counterfeits (4)
• FDA pushes DSCSA serialisation enforcement deadline to 2018 (5)
• Pharma’s digital supply chain transformation (6)

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Evren Ozkaya PhD is the Founder and CEO of Supply Chain Wizard: a full-service global consulting firm specialising in serialisation and traceability as well as supply chain strategy and operational transformation programmes. Supply Chain Wizard offers products and services targeting serialisation and supply chain transformation initiatives, along with a team of consultants providing comprehensive support towards cost-effective compliance with serialisation mandates and post-go-live operational support. Email:
spacer
Dr Evren Ozkaya
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Winners of the 2021 CPhI Pharma Awards have now been announced

Milan, 10 November 2021: CPhI Worldwide announces the winners of the 18th edition of the CPhI Pharma Awards, hosted live in Milan, with winners spanning some 10 distinct categories. The Awards seek to recognise ‘Excellence in Pharma’ , assessing entries from the industry leading companies and individuals.
More info >>

White Papers

Mouse Models for Evaluation of Vaccines and Therapeutics Against Staphylococcal Infections

IBT Bioservices

Introduction Staphylococcus aureus (SA) is a ubiquitous, formidable Gram-positive pathogen associated with skin and soft tissue, as well as lifethreatening systemic infections. SA is a leading cause of hospital- and community-associated infections worldwide, affecting humans and animals. The wide range of pathologies reflects the diverse abilities of this microbe to escape the innate and adaptive immune response using virulence factors. Since its first emergence in the 1960s methicillin-resistant SA (MRSA) has become endemic in hospitals and healthcare settings worldwide. In the 1990s, community associated MRSA strains (CA-MRSA) emerged, and are spreading worldwide posing a major global challenge.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement